Sulfonamide hypersensitivity syndrome

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 22:44, 26 May 2016 (→‎top: CS1 maintenance: vauthors/veditors or enumerate multiple authors/editors; WP:GenFixes on, using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sulfonamide hypersensitivity syndrome

Sulfonamide hypersensitivity syndrome is similar to anticonvulsant hypersensitivity syndrome, but the onset is often sooner in the treatment course, generally after 7–14 days of therapy.[1]: 118–9 

It is considered immune-mediated.[2]

See also

References

  1. ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0721629210.
  2. ^ Cribb AE, Pohl LR, Spielberg SP, Leeder JS (August 1997). "Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins". J. Pharmacol. Exp. Ther. 282 (2): 1064–71. PMID 9262376.